at the heart of value creation analysts company presentation august 2005 zurich london frankfurt alice huxley ceo & founder konrad p wirz cfo jessica mann medical director ben tan head business development licensing chris jensen pharmacology nick miles communications investor relations analyst 2 disclaimer this document on speedel holding ag or contains forward looking statements concerning s future activities revenues operations and expenditures these represent expectations management as date release actual results could differ materially from those due to a number factors including but explicitly not limited i partners ability successfully complete pre clinical within projected time frame obtain timely regulatory approvals license rights other proprietary protections for product candidates ii content timing decisions made by us food drug administration fda
